Quantcast

Posts Tagged: myriad genetics


On the very same day that the U S jobs report shows unexpectedly weak growth the Federal Court of Australia issued a ruling directly opposite to the ruling rendered by the United States Supreme Court relative to gene patents…

Continue Reading

Written by David J Kappos former Director of the USPTO The language of the Myriad decision did not on its face mandate drastic innovation-dampening action The Supreme Court chose to narrowly decide the Myriad case stating that a DNA…

Continue Reading

The U S Department of Commerce s United States Patent and Trademark Office USPTO will host a public forum on May at the USPTO headquarters in Alexandria Virginia to solicit feedback from organizations and individuals on its recent guidance…

Continue Reading

As the end of approaches and I look back on what has transpired I am saddened to see that through the year patent rights have continued to erode Make no mistake about it at every turn patent rights are…

Continue Reading

Mark Lemley's Firm Files DJ Against Myriad in Northern California ----- Promise Not to Infringe Insufficient in ANDA Litigation ----- Licensing Deals Stall in Pharmaceutical Sector in First Half of ----- Mylan Settles with FTC over Agila Acquisition from…

Continue Reading

Senate Judiciary Committee Chairman Patrick Leahy D-VT asked NIH in a July letter to force compulsory licensing of Myriad s BRCA breast and ovarian cancer genetic test under the march-in rights provision of the Bayh-Dole Act Myriad received an…

Continue Reading

By holding that Myriad s claimed cDNA was patent-eligible Thomas opinion reaffirms the major holding in Diamond v Chakrabarty that claimed subject matter which truly only the hand of man can make not simply snipped out of mother nature…

Continue Reading

The baffling aspect of the opinion is that the Court seems to agree that both the DNA of claim and the DNA of claim are man-made and do not occur in nature Of claim the Court states that isolating…

Continue Reading

USPTO to Examiners As of today naturally occurring nucleic acids are not patent eligible merely because they have been isolated Examiners should now reject product claims drawn solely to naturally occurring nucleic acids or fragments thereof whether isolated or…

Continue Reading

You can expect a near complete cessation in many areas of personalized medicine If creating something in a lab such as a composite cDNA does not make the underlying claims patent eligible because what results is indistinguishable from what…

Continue Reading

One of the central policy issues injected into the current case of AMP v Myriad Genetics is whether the BRCA patents are good for innovation and ultimately for patients Specifically ACLU and PubPat allege that the patents have hindered…

Continue Reading

Since my last article here on IPWatchdog com the pharmaceutical industry has been simply overflowing with interesting developments including the US Supreme Court hearing arguments concerning three significant cases The first case argued at the Supreme Court will determine…

Continue Reading